Jonathan M. Cohen - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Jonathan Cohen
Issuer symbol: N/A
Transactions as of: 17 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 19 Feb 2026, 17:52:33 UTC
Next filing: 04 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cohen Jonathan M	Chief Executive Officer, Director, 10%+ Owner	C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG	/s/ Jonathan Cohen	19 Feb 2026	0002111543

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding		Common Stock						1,366,400	17 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding		Stock Option							17 Feb 2026	Common Stock	388,000	$1.74	Direct	F1
holding		Stock Option							17 Feb 2026	Common Stock	125,000	$2.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 388,000 shares of common stock, with 194,000 shares vested on the date of the grant and the remaining shares vested in equal monthly installments over the following 24 months.
F2	On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 125,000 shares of common stock, with 31,250 shares vesting on the date of grant and the remaining shares vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.